Analyst Ratings For Agilent Technologies (NYSE:A)
Today, Deutsche Bank reiterated its Buy rating on Agilent Technologies (NYSE:A) with a price target of $90.00.
There are 7 Buy Ratings, 2 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Agilent Technologies (NYSE:A) is Buy with a consensus target price of $84.1667 per share, a potential 7.14% upside.
Some recent analyst ratings include
- 2/21/2019-Agilent Technologies (NYSE:A) had its Buy rating reiterated by Deutsche Bank with a $90.00 price target
- 2/20/2019-Agilent Technologies (NYSE:A) had its Buy rating reiterated by Robert W. Baird with a $82.00 price target
- 1/2/2019-Agilent Technologies (NYSE:A) has coverage initiated with a Buy ➝ Buy rating and $77.00 price target
- 11/12/2018-Agilent Technologies (NYSE:A) gets downgraded to Neutral by Cleveland Research
About Agilent Technologies (NYSE:A)
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides reagents, instruments, software, and consumables; arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment focused on production of synthesized oligonucleotides for use as active pharmaceutical ingredients. The Agilent CrossLab segment offers GC and LC columns, sample preparation products, custom chemistries, and various laboratory instrument supplies; and startup, operational, training, compliance support, and software as a service, as well as asset management and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was founded in 1999 and is headquartered in Santa Clara, California.
Recent Trading Activity for Agilent Technologies (NYSE:A)
Shares of Agilent Technologies closed the previous trading session at 78,56 up +1,07 1,38 % with 77.33 shares trading hands.